Literature DB >> 23503527

Targeting Toll-like receptors with small molecule agents.

Xiaohui Wang1, Christina Smith, Hang Yin.   

Abstract

Toll-like receptors (TLRs) are type I transmembrane proteins that are key regulators of both innate and adaptive immune responses. To protect the host from viral and bacterial threats, TLRs trigger a pro-inflammatory immune response by detecting pathogen and danger associated molecular patterns. Considerable evidence has accumulated to show that the dysregulation of TLR signaling contributes to the development and progression of numerous diseases. Therefore, TLRs are emerging as important drug discovery targets. Currently, there is great interest in the development of TLR small molecule modulators for interrogating TLR signaling and treating diseases caused by TLR signaling malfunctions. In this tutorial review, we will outline methods for the discovery of TLR small molecule modulators and the up-to-date progress in this field. Small molecules targeting TLRs not only provide an opportunity to identify promising drug candidates, but also unveil knowledge regarding TLR signaling pathways.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23503527      PMCID: PMC3665707          DOI: 10.1039/c3cs60039d

Source DB:  PubMed          Journal:  Chem Soc Rev        ISSN: 0306-0012            Impact factor:   54.564


  50 in total

1.  A novel cyclohexene derivative, ethyl (6R)-6-[N-(2-Chloro-4-fluorophenyl)sulfamoyl]cyclohex-1-ene-1-carboxylate (TAK-242), selectively inhibits toll-like receptor 4-mediated cytokine production through suppression of intracellular signaling.

Authors:  Masayuki Ii; Naoko Matsunaga; Kaoru Hazeki; Kazuyo Nakamura; Katsunori Takashima; Tsukasa Seya; Osamu Hazeki; Tomoyuki Kitazaki; Yuji Iizawa
Journal:  Mol Pharmacol       Date:  2005-12-22       Impact factor: 4.436

2.  MD-2 enables Toll-like receptor 2 (TLR2)-mediated responses to lipopolysaccharide and enhances TLR2-mediated responses to Gram-positive and Gram-negative bacteria and their cell wall components.

Authors:  R Dziarski; Q Wang; K Miyake; C J Kirschning; D Gupta
Journal:  J Immunol       Date:  2001-02-01       Impact factor: 5.422

3.  Establishment of dorsal-ventral polarity in the Drosophila embryo: the induction of polarity by the Toll gene product.

Authors:  K V Anderson; L Bokla; C Nüsslein-Volhard
Journal:  Cell       Date:  1985-10       Impact factor: 41.582

4.  Discovery of novel and potent small-molecule inhibitors of NO and cytokine production as antisepsis agents: synthesis and biological activity of alkyl 6-(N-substituted sulfamoyl)cyclohex-1-ene-1-carboxylate.

Authors:  Masami Yamada; Takashi Ichikawa; Masayuki Ii; Mie Sunamoto; Katsumi Itoh; Norikazu Tamura; Tomoyuki Kitazaki
Journal:  J Med Chem       Date:  2005-11-17       Impact factor: 7.446

5.  Toll-like receptor 4 region Glu24-Lys47 is a site for MD-2 binding: importance of CYS29 and CYS40.

Authors:  Chiaki Nishitani; Hiroaki Mitsuzawa; Hitomi Sano; Takeyuki Shimizu; Norio Matsushima; Yoshio Kuroki
Journal:  J Biol Chem       Date:  2006-10-20       Impact factor: 5.157

6.  The evolution of vertebrate Toll-like receptors.

Authors:  Jared C Roach; Gustavo Glusman; Lee Rowen; Amardeep Kaur; Maureen K Purcell; Kelly D Smith; Leroy E Hood; Alan Aderem
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-23       Impact factor: 11.205

Review 7.  Eritoran tetrasodium (E5564) treatment for sepsis: review of preclinical and clinical studies.

Authors:  Amisha Barochia; Steven Solomon; Xizhong Cui; Charles Natanson; Peter Q Eichacker
Journal:  Expert Opin Drug Metab Toxicol       Date:  2011-02-17       Impact factor: 4.481

8.  Toll-like receptor 2 antagonists. Part 1: preliminary SAR investigation of novel synthetic phospholipids.

Authors:  Mark R Spyvee; Huiming Zhang; Lynn D Hawkins; Jesse C Chow
Journal:  Bioorg Med Chem Lett       Date:  2005-10-19       Impact factor: 2.823

9.  Novel TLR4-antagonizing peptides inhibit LPS-induced release of inflammatory mediators by monocytes.

Authors:  Qing-Wu Yang; Ling Mou; Feng-Lin Lv; Pei-Fang Zhu; Zheng-Guo Wang; Jian-Xin Jiang; Jing-Zhou Wang
Journal:  Biochem Biophys Res Commun       Date:  2005-04-15       Impact factor: 3.575

10.  Structure-activity relationship of synthetic toll-like receptor 4 agonists.

Authors:  Axel G Stöver; Jean Da Silva Correia; Jay T Evans; Christopher W Cluff; Mark W Elliott; Eric W Jeffery; David A Johnson; Michael J Lacy; Jory R Baldridge; Peter Probst; Richard J Ulevitch; David H Persing; Robert M Hershberg
Journal:  J Biol Chem       Date:  2003-10-21       Impact factor: 5.157

View more
  30 in total

1.  Multivalent Antigens for Promoting B and T Cell Activation.

Authors:  Nitasha R Bennett; Daniel B Zwick; Adam H Courtney; Laura L Kiessling
Journal:  ACS Chem Biol       Date:  2015-06-02       Impact factor: 5.100

2.  Discovery and Structure-Activity Relationships of the Neoseptins: A New Class of Toll-like Receptor-4 (TLR4) Agonists.

Authors:  Matthew D Morin; Ying Wang; Brian T Jones; Lijing Su; Murali M R P Surakattula; Michael Berger; Hua Huang; Elliot K Beutler; Hong Zhang; Bruce Beutler; Dale L Boger
Journal:  J Med Chem       Date:  2016-04-25       Impact factor: 7.446

Review 3.  Strategies for designing synthetic immune agonists.

Authors:  Tom Y-H Wu
Journal:  Immunology       Date:  2016-07-11       Impact factor: 7.397

4.  Rationally Designed Macrocyclic Peptides as Synergistic Agonists of LPS-Induced Inflammatory Response.

Authors:  Meng Gao; Nir London; Kui Cheng; Ryo Tamura; Jialin Jin; Ora Schueler-Furman; Hang Yin
Journal:  Tetrahedron       Date:  2014-10-21       Impact factor: 2.457

5.  Potent and Selective Amidopyrazole Inhibitors of IRAK4 That Are Efficacious in a Rodent Model of Inflammation.

Authors:  William T McElroy; Zheng Tan; Ginny Ho; Sunil Paliwal; Guoqing Li; W Michael Seganish; Deen Tulshian; James Tata; Thierry O Fischmann; Christopher Sondey; Hong Bian; Loretta Bober; James Jackson; Charles G Garlisi; Kristine Devito; James Fossetta; Daniel Lundell; Xiaoda Niu
Journal:  ACS Med Chem Lett       Date:  2015-05-12       Impact factor: 4.345

Review 6.  Current and Future Issues in the Development of Spinal Agents for the Management of Pain.

Authors:  Tony L Yaksh; Casey J Fisher; Tyler M Hockman; Ashley J Wiese
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

Review 7.  Basic/Translational Development of Forthcoming Opioid- and Nonopioid-Targeted Pain Therapeutics.

Authors:  Nebojsa Nick Knezevic; Ajay Yekkirala; Tony L Yaksh
Journal:  Anesth Analg       Date:  2017-11       Impact factor: 5.108

Review 8.  Toll-Like Receptor-4 Signaling Drives Persistent Fibroblast Activation and Prevents Fibrosis Resolution in Scleroderma.

Authors:  Swati Bhattacharyya; Kim S Midwood; Hang Yin; John Varga
Journal:  Adv Wound Care (New Rochelle)       Date:  2017-10-01       Impact factor: 4.730

9.  A Decoy Peptide that Disrupts TIRAP Recruitment to TLRs Is Protective in a Murine Model of Influenza.

Authors:  Wenji Piao; Kari Ann Shirey; Lisa W Ru; Wendy Lai; Henryk Szmacinski; Greg A Snyder; Eric J Sundberg; Joseph R Lakowicz; Stefanie N Vogel; Vladimir Y Toshchakov
Journal:  Cell Rep       Date:  2015-06-18       Impact factor: 9.423

10.  Diprovocims: A New and Exceptionally Potent Class of Toll-like Receptor Agonists.

Authors:  Matthew D Morin; Ying Wang; Brian T Jones; Yuto Mifune; Lijing Su; Hexin Shi; Eva Marie Y Moresco; Hong Zhang; Bruce Beutler; Dale L Boger
Journal:  J Am Chem Soc       Date:  2018-10-16       Impact factor: 15.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.